What is Medical Weight Loss?
Medical weight loss is a structured program supervised by healthcare providers that’s designed to help individuals lose weight safely and effectively. Such programs are tailored to the unique needs of each patient, including nutritional counseling, behavioral therapy, physical activity guidance, and, when appropriate, prescription medications. The focus is to lose weight, but the real goal is to improve overall health and reduce the risk of obesity-related diseases like diabetes, hypertension, and cardiovascular disease.
A key component of many modern medical weight loss programs is the use of GLP-1 RAs (glucagon-like peptide-1 receptor agonists). These medications mimic the action of the hormone GLP-1 that our bodies naturally make, which is to regulate appetite and blood sugar. There are several GLP-1 injectable medications approved for chronic weight management in adults with obesity or overweight and related health conditions, including Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide), as well as the recently available Wegovy oral tablet.
How Do GLP-1 Medications Work?
GLP-1 medications work by mimicking the effects of the incretin hormones that our bodies naturally produce to help regulate blood sugar levels and appetite. When food is consumed, GLP-1 is released from the gut, signaling the brain to promote satiety (a feeling of fullness) and slowing gastric emptying. This dual action helps reduce overall calorie intake and supports sustained weight loss.
Tirzepatide, a dual-agonist medication, targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors to further enhance insulin secretion and reduce hunger.
Is Medical Weight Loss Better Than Bariatric Surgery?
The question of whether one is superior to another is not as simple as it sounds. The short answer is that one approach is not inherently better than the other because they each occupy an important place in the continuum of obesity care.
Weight loss surgeries, including both gastric bypass and sleeve gastrectomy, are still the gold standard for achieving significant, long-term weight loss, particularly in individuals with severe obesity or those who have not responded to other treatments. However, surgery is invasive, requires lifelong follow-up, and is not appropriate for everyone.
GLP-1 medications are a less invasive alternative that’s very effective for patients who are not good candidates for surgery or prefer a non-surgical option. GLP-1 therapy can help patients lose weight and improve metabolic health, sometimes delaying or eliminating the need for surgery in individuals with a lower BMI. However, recent studies suggest that without long-term lifestyle modifications, the weight lost while on the medication can rebound shortly after stopping it.1 GLP-1 medications are typically appropriate for individuals with lower-to-moderate obesity (a BMI of around 30, or 27 with weight-related conditions), whereas bariatric surgery is generally reserved for moderate-to-severe obesity (a BMI of 40+, or 35+ with comorbidities).
It is not uncommon for patients to start with medical weight loss and later transition to bariatric surgery. Using GLP-1 medications before surgery can help patients lose initial weight, lower operative risks, and improve metabolic profiles by addressing conditions like diabetes and hypertension, making surgery safer. After surgery, these medications can be valuable for patients experiencing weight regain or for those who do not reach their target weight goals. (Note: GLP-1 RA use has to be stopped prior to surgery. GLP-1 therapy intentionally causes a delay in gastric emptying [gastroparesis] and creates a high risk of pulmonary aspiration during anesthesia for surgeries.)
Medical weight loss, particularly with the advent of GLP-1 medications, gives people more options for treating obesity. When integrated thoughtfully with bariatric surgery, lifestyle modifications, and behavioral interventions, comprehensive, personalized care can be achieved. The synergy leads to better health outcomes, happier patients, and more lasting weight control.
- Quimbayo-Cifuentes A. F. (2026). Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap. Cureus, 18(2), e104259. https://doi.org/10.7759/cureus.104259.